Studies on the peripheral mode of action of dihydroergotamine in human and canine veins.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002744:Chlorpheniramine / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004878:Ergotamine / Q000494:pharmacology*; D005268:Femoral Vein / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology; D012501:Saphenous Vein / Q000187:drug effects; D014680:Veins / Q000187:drug effects*
D011453:Prostaglandins; D010643:Phenoxybenzamine; D002744:Chlorpheniramine; D001285:Atropine; D011433:Propranolol; D004878:Ergotamine; D009638:Norepinephrine; D007213:Indomethacin; D008784:Methysergide; D010646:Phentolamine